drugset / Trial / NCT02419469
Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if a chemotherapy combination called augmented Berlin-Frankfurt-Munster (BFM), when also combined with ofatumumab or rituximab, can help to control precursor-B ALL or LL in patients who are 12-30 years of age. The safety of these drug combinations will also be studied. Augmented BFM is made up of daunorubicin, vincristine, prednisone, dexamethasone, PEG asparaginase, and methotrexate.
Timeline
- Start
- 2015-11-13
- Primary completion
- 2017-06-22
- Completion
- 2017-06-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 1 g | Intravenous |
| Subject | Cytarabine | Small molecule | 75 mg/m2 | Intrathecal |
| Subject | Cytarabine | Small molecule | 100 mg | Intrathecal |
| Subject | Daunorubicin | Small molecule | 25 mg/m2 | Intravenous |
| Subject | Dexamethasone | Small molecule | 6 mg/m2 | Oral |
| Subject | Dexamethasone | Small molecule | 10 mg/m2 | Oral |
| Subject | Doxorubicin | Other / unclassified | 25 mg/m2 | Intravenous |
| Subject | MERCAPTOPURINE ANHYDROUS | Small molecule | 60 mg/m2 | Oral |
| Subject | MERCAPTOPURINE ANHYDROUS | Small molecule | 75 mg/m2 | Oral |
| Subject | Methotrexate | Small molecule | 12 mg | Intrathecal |
| Subject | Methotrexate | Small molecule | 20 mg/m2 | Intrathecal |
| Subject | Methotrexate | Small molecule | 100 mg/m2 | Intrathecal |
| Subject | Ofatumumab | Monoclonal antibody | 300 mg | Intravenous |
| Subject | Ofatumumab | Monoclonal antibody | 2000 mg | Intravenous |
| Subject | Pegaspargase | Protein / enzyme biologic | 2000 iu | Intravenous |
| Subject | Prednisone | Other / unclassified | 60 mg/m2 | Oral |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Subject | Thioguanine | Small molecule | 60 mg/m2 | Oral |
| Subject | Vincristine | Small molecule | 1.5 mg/m2 | Intravenous |